Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 6, 2026Discover OncologyOpen Access

Investigating the effects of olanzapine on appetite and weight in patients with cancer in a systematic review

View Full Paper
Ask AI
Bookmark
Share

Authors

MTMarie Charlotte Renaux TorresKSKamélia SmatiPNPeter Noujaim

Discussion

Loading...

Member takes

Overview

Systematic review evaluates olanzapine's impact on appetite and body weight in cancer patients, suggesting orexigenic effects.

Key Points

  • The central aim is to evaluate how olanzapine affects appetite and body weight in cancer patients.
  • Included randomized controlled trials and observational studies
  • Conducted literature search in Medline, Embase, and Cochrane Library
  • Assessed risk of bias using Cochrane RoB2 and ROBINS-I methods.
  • Increased appetite reported in 10 of 14 studies using olanzapine 2.5-10 mg/day for 3 days to 12 weeks.
  • Weight gain observed in 2 RCTs using olanzapine 2.5-5 mg/day for 8-12 weeks.
  • Methodological quality varied, with most studies having high risk of bias, indicating substantial limitations.

Cite This Study

Torres et al. (2026) studied this question.

synapsesocial.com/papers/6a23b8c571a5da9775e74e60https://doi.org/10.1007/s12672-026-05346-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Olanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial2025
  2. 2A network meta-analysis of anorexia treatments in disease and old age: pharmacogenomics, the gut-brain axis and artificial neural nets. Where are we?2025
  3. 3The Impact of Adjunctive Aripiprazole on Olanzapine‐Induced Metabolic Adverse Effects in Patients With Schizophrenia: A Systematic Review2025
  4. 4The effect of olanzapine on diabetes related index in humans: a systematic review and meta-analysis of randomized controlled trials2026
  5. 5Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials2025